Sangamo Therapeutics

552 articles with Sangamo Therapeutics

• Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will present at the following investor conferences

• Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

  8/10/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August 12, 2020 at 2:55 p.m. Eastern Time. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About S

• Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results

  8/5/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.

• Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

  7/30/2020

  Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

• Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast

  7/29/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020.

• 

  In Reorganization, Sangamo Splits R&D Unit into Separate Entities

  6/25/2020

  The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.

• Sangamo Announces R&D Organization Changes

  6/24/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway. Jason Fontenot, Senior Vice President, Cell Therapy, will assume the role of Interim Head of Research. The heads of research and development will report to CEO Sandy Macrae.

• Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

  6/18/2020

  Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A

• 

  Pfizer and Sangamo Release Updated Gene Therapy Data in Hemophilia A

  6/18/2020

  Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.

• Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference

  5/29/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About Sangamo Therapeutics Sangam

• Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference

  5/12/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET. The audio presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About Sangamo Therapeutics

• Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results

  5/11/2020

  Sangamo Therapeutics, Inc., a genomic medicine company, reported first quarter 2020 financial results and recent business highlights.

• Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting

  5/7/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.

• Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast

  5/4/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020.

• Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy

  4/28/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.

• 

  BioSpace Movers & Shakers, April 24

  4/24/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers.

• Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells

  4/21/2020

  Mogrify Ltd and Sangamo Therapeutics announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells and embryonic stem cells and Sangamo’s zinc finger protein gene-engineered chimeric antigen receptor regulatory T cell technology.

• Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells

  4/21/2020

  Mogrify Ltd (Mogrify ® ), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induce

• Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer

  4/17/2020

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development. Mr. McClung’s appointment is the latest in the evolution of Sangamo’s leadership implemented over the last three years as t

• Sangamo Announces Closing of Biogen Collaboration Agreement

  4/9/2020

  Sangamo has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by May 8, 2020